Calcium channel blockers for primary pulmonary hypertension
Calcium channel blockers for primary pulmonary hypertension
Cochrane Review
8 SoF Entries
Summary of Findings
Key results and quality assessments using GRADE methodology
| Outcome | Effect | Participants | Studies | Certainty |
|---|---|---|---|---|
|
Changes in intensity of pain (VAS) when tested through air blast stimuli - short term (0 to 24 hours)
placebo/no treatment |
2.24 | - | - | Not assessed |
|
Changes in intensity of pain (VAS) when tested through air blast stimuli - medium term (24 hours to 2 months)
placebo/no treatment |
2.46 | - | - | Not assessed |
|
Changes in intensity of pain (VAS) when tested through air blast stimuli - long term (more than 2 months)
placebo/no treatment |
2.6 | - | - | Not assessed |
|
Adverse events
placebo/no treatment |
nan | - | - | Not assessed |
|
Patient-reported quality of life
placebo/no treatment |
nan | - | - | Not assessed |
|
Changes in intensity of pain (VAS) when tested through tactile stimuli - short term (0 to 24 hours)
placebo/no treatment |
0.67 | - | - | Not assessed |
|
Changes in intensity of pain (VAS) when tested through tactile stimuli - medium term (24 hours to 2 months)
placebo/no treatment |
1.73 | - | - | Not assessed |
|
Changes in intensity of pain (VAS) when tested through tactile stimuli - long term (more than 2 months)
placebo/no treatment |
3.52 | - | - | Not assessed |
GRADE Certainty of Evidence:
High
Very confident in the effect estimate
Moderate
Moderately confident in the effect estimate
Low
Limited confidence in the effect estimate
Very Low
Very little confidence in the effect estimate
Review Information
| Review ID: | CD009434 |
| Outcomes: | 8 assessed |
Related Content
Evidence Quality Distribution:
Not assessed:
8